Concord Drugs Q1 Results
- BSE: 538965
- NSE: -
- ISIN: INE858L01010
- Sector: Biotechnology & Drugs
BSE
71.00
-1.50 (-2.07%)
-1.50 (-2.07%)Volume3.80 K
Updated: Thu 8 Oct, 2026 | 15:18:16
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q1 Results Highlights
- Total Income₹20.94 Cr.(53.89%)
- Operating Profit₹1.93 Cr.(198.13%)
- Profit After Tax₹1.11 Cr.(847.28%)
- Operating Margin9.23%(93.73%)
Note: Comparison is on YoY basis
Quarterly - Concord Drugs Q1 Results
*All figures in crores except per share values
| Fiscal Period | Jun 26 | Mar 26 | QoQ Comp | Jun 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 19.01 | 36.76 | -48.29% | 11.20 | 46.67% |
| Depreciation/ Amortization | 0.35 | 0.35 | -0.99% | 0.34 | -5.03% |
| Operating Income | 1.93 | 1.13 | 70.65% | 0.49 | 198.13% |
| Net Income | 1.11 | 0.53 | 110.94% | 0.03 | 847.28% |
| Other Operating Expenses Total | 0.49 | 0.53 | -8.44% | 0.38 | 70.56% |
| Net Income Before Taxes | 1.54 | 0.75 | 106.65% | 0.04 | 875.93% |
| Total Revenue | 20.94 | 37.89 | -44.74% | 11.69 | 53.89% |
| Selling/ General/ Admin Expenses Total | 1.26 | 1.75 | -28.35% | 1.46 | 41.74% |
| Diluted Normalized EPS | 0.85 | 1.04 | -18.32% | 0.03 | 608.33% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.